UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 237

Sortiert nach

S3 guideline hepatitis C addendum

Zeitschrift fur Gastroenterologie, 2015-04, Vol.53 (4), p.320

2015

Volltextzugriff (PDF)

Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe

Journal of viral hepatitis, 2018-07, Vol.25 (7), p.811-817

2018

Volltextzugriff (PDF)

Acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in chronic hepatitis B

Journal of viral hepatitis, 2013-04, Vol.20 (4), p.240-247

2013

Volltextzugriff (PDF)

Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection

Journal of hepatology, 2017, Vol.66 (1), p.S499-S499

2017

Volltextzugriff (PDF)

Real‐world experience with the all‐oral, interferon‐free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry

Journal of viral hepatitis, 2017-10, Vol.24 (10), p.840-849

2017

Volltextzugriff (PDF)

Real-world effectiveness and cost per SVR of Sofosbuvir/Velpatasvir chronic hepatitis C treatment

Journal of hepatology, 2017, Vol.66 (1), p.S730-S730

2017

Volltextzugriff (PDF)

Letter: telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis

Alimentary pharmacology & therapeutics, 2014-06, Vol.39 (11), p.1342-1344

2014

Volltextzugriff (PDF)

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B

Gastroenterology (New York, N.Y. 1943), 2004-01, Vol.126 (1), p.91-101

2004

Volltextzugriff (PDF)

Real-world effectiveness and safety of Ombitasvir, Paritaprevir/r ± Dasabuvir ± Ribavirin in patients receiving opiate substitution therapy: results from the German observational study LIFE-C

Journal of hepatology, 2017, Vol.66 (1), p.S530-S530

2017

Volltextzugriff (PDF)

LP32 : Real-world effectiveness of ledipasvir/sofosbuvir 8 weeks chronic hepatitis C treatment

Journal of hepatology, 2015-04, Vol.62, p.S280-S280

2015

Volltextzugriff (PDF)

Real-World Effectiveness of Ledipasvir/Sofosbuvir 8 Weeks Chronic Hepatitis C Treatment

Journal of hepatology, 2016, Vol.64 (2), p.S811-S811

2016

Volltextzugriff (PDF)

Real-World Effectiveness and Cost per Sustained Viral Response of Ledipasvir/Sofosbuvir Chronic Hepatitis C Treatment

Journal of hepatology, 2016, Vol.64 (2), p.S809-S810

2016

Volltextzugriff (PDF)

Real-World Data on the use of Ribavirin with Ombitasvir/Paritaprevir/R with or without Dasabuvir in HCV Genotype 1 or 4-Infected Patients from the German Hepatitis C Registry

Journal of hepatology, 2016, Vol.64 (2), p.S826-S826

2016

Volltextzugriff (PDF)

Effectiveness, safety and quality of life in patients treated with Ombitasvir/Paritaprevir/r ± Dasabuvir ± Ribavirin under real-life conditions – data from the German observational study LIFE-C

Journal of hepatology, 2017, Vol.66 (1), p.S530-S530

2017

Volltextzugriff (PDF)

Strong decrease of patients with advanced liver disease and more adherence problems to HCV therapy as DAA regimen enter third year of existence in Germany

Journal of hepatology, 2017, Vol.66 (1), p.S522-S522

2017

Volltextzugriff (PDF)

Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R)

Journal of hepatology, 2017, Vol.66 (1), p.S519-S520

2017

Volltextzugriff (PDF)

Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1

Journal of hepatology, 2017, Vol.66 (1), p.S729-S730

2017

Volltextzugriff (PDF)

Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R)

Journal of hepatology, 2017, Vol.66 (1), p.S55-S55

2017

Volltextzugriff (PDF)

P0789 : Effectiveness, safety and cost per SVR in GT4 hepatitis C patients treated with sofosbuvir-based therapies in real clinical practice: A Franco-German experience (SOFEX-4)

Journal of hepatology, 2015-04, Vol.62, p.S628-S628

2015

Volltextzugriff (PDF)

P0777 : Sofosbuvir-based treatment under real life conditions in Germany (The sofger trial)

Journal of hepatology, 2015-04, Vol.62, p.S622-S622

2015

Volltextzugriff (PDF)

Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Wks in Genotype 1 (GT1) Treatment-Naïve Non-Cirrhotic Patients with HCV Viral Load <6 Million IU/mL (6M); Acomparative Analysis of the Phase-3 ION-3 Data to Real World Effectiveness

Journal of hepatology, 2016, Vol.64 (2), p.S810-S810

2016

Volltextzugriff (PDF)

Efficacy and Tolerability of Simeprevir and Daclatasvir for 12 or 24 Weeks in HCV Genotype 1b-Infected Treatment-Naïve Patients with Advanced Fibrosis or Compensated Cirrhosis

Journal of hepatology, 2016, Vol.64 (2), p.S754-S754

2016

Volltextzugriff (PDF)

Resistance patterns in patients with chronic hepatitis C genotype 4 infection and treatment outcome

Journal of hepatology, 2017, Vol.66 (1), p.S525-S525

2017

Volltextzugriff (PDF)

Failure with DAA Regimens in a High Volume Treatment Center under Real Life Conditions

Journal of hepatology, 2016, Vol.64 (2), p.S782-S782

2016

Volltextzugriff (PDF)

Treatment of Patients with Hepatitis C Virus (HCV) Genotype 3 Infection in the Era of Direct Acting Antivirals (DAA): Data from the German Hepatitis C-Registry (DHC-R)

Journal of hepatology, 2016, Vol.64 (2), p.S794-S794

2016

Volltextzugriff (PDF)

1 – 25 von 237

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(235)
Mit Volltextzugriff
(220)

Publikationsform

Sprache

Englisch
(229)
Japanisch
(13)
Deutsch
(13)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Gastroenterology And Hepatology
(82)
Science & Technology
(75)
Life Sciences & Biomedicine
(70)
Humans
(59)
Female
(48)
Male
(47)
Gastroenterology & Hepatology
(46)
Middle Aged
(42)
Adult
(39)
Aged
(28)
Biological And Medical Sciences
(25)
Medical Sciences
(25)
Hepatitis C
(24)
Infectious Diseases
(24)
Hepatitis C, Chronic - Drug Therapy
(23)
Antiviral Agents - Therapeutic Use
(22)
Treatment Outcome
(21)
Hepatitis
(18)
Interferon
(18)
Antiviral Agents
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

S3 guideline hepatitis C addendum

Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe

Acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in chronic hepatitis B

Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection

Real‐world experience with the all‐oral, interferon‐free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry

Real-world effectiveness and cost per SVR of Sofosbuvir/Velpatasvir chronic hepatitis C treatment

Letter: telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B

Real-world effectiveness and safety of Ombitasvir, Paritaprevir/r ± Dasabuvir ± Ribavirin in patients receiving opiate substitution therapy: results from the German observational study LIFE-C

LP32 : Real-world effectiveness of ledipasvir/sofosbuvir 8 weeks chronic hepatitis C treatment

Real-World Effectiveness of Ledipasvir/Sofosbuvir 8 Weeks Chronic Hepatitis C Treatment

Real-World Effectiveness and Cost per Sustained Viral Response of Ledipasvir/Sofosbuvir Chronic Hepatitis C Treatment

Real-World Data on the use of Ribavirin with Ombitasvir/Paritaprevir/R with or without Dasabuvir in HCV Genotype 1 or 4-Infected Patients from the German Hepatitis C Registry

Effectiveness, safety and quality of life in patients treated with Ombitasvir/Paritaprevir/r ± Dasabuvir ± Ribavirin under real-life conditions – data from the German observational study LIFE-C

Strong decrease of patients with advanced liver disease and more adherence problems to HCV therapy as DAA regimen enter third year of existence in Germany

Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R)

Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1

Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R)

P0789 : Effectiveness, safety and cost per SVR in GT4 hepatitis C patients treated with sofosbuvir-based therapies in real clinical practice: A Franco-German experience (SOFEX-4)

P0777 : Sofosbuvir-based treatment under real life conditions in Germany (The sofger trial)

Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Wks in Genotype 1 (GT1) Treatment-Naïve Non-Cirrhotic Patients with HCV Viral Load <6 Million IU/mL (6M); Acomparative Analysis of the Phase-3 ION-3 Data to Real World Effectiveness

Efficacy and Tolerability of Simeprevir and Daclatasvir for 12 or 24 Weeks in HCV Genotype 1b-Infected Treatment-Naïve Patients with Advanced Fibrosis or Compensated Cirrhosis

Resistance patterns in patients with chronic hepatitis C genotype 4 infection and treatment outcome

Failure with DAA Regimens in a High Volume Treatment Center under Real Life Conditions

Treatment of Patients with Hepatitis C Virus (HCV) Genotype 3 Infection in the Era of Direct Acting Antivirals (DAA): Data from the German Hepatitis C-Registry (DHC-R)

Suchergebnisse filtern